Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MRX-2843 (UNC2371) 是ATP 竞争性的、具有口服活性的MERTK 和FLT3酪氨酸激酶抑制剂 (TKI),它们的IC50分别为 1.3 nM 和 0.64 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 497 | 现货 | ||
5 mg | ¥ 1,490 | 现货 | ||
10 mg | ¥ 2,390 | 现货 | ||
25 mg | ¥ 4,130 | 现货 | ||
50 mg | ¥ 5,890 | 现货 | ||
100 mg | ¥ 8,160 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,580 | 现货 |
产品描述 | MRX-2843 (UNC2371) is a potent and orally active inhibitor of MERTK and FLT3(IC50s of 1.3 nM and 0.64 nM, respectively). |
靶点活性 | FLT3:0.64 nM, MerTK:1.3 nM |
体外活性 | MRX-2843, a type 1 small-molecule tyrosine kinase inhibitor that abrogates activation of both MERTK and FLT3 and their downstream effectors.?MRX-2843 treatment induces apoptosis and inhibits colony formation in AML cell lines and primary patient samples expressing MERTK and/or FLT3-ITD, with a wide therapeutic window compared with that of normal human cord blood cells[1]. |
体内活性 | In murine orthotopic xenograft models, once-daily oral therapy prolonged survival 2- to 3-fold over that of vehicle-treated controls.?Additionally, MRX-2843 retained activity against quizartinib-resistant FLT3-ITD-mutant proteins with clinically relevant alterations at the D835 or F691 loci and prolonged survival in xenograft models of quizartinib-resistant AML.?Together, these observations validate MRX-2843 as a translational agent and support its clinical development for the treatment of AML[1]. |
别名 | UNC2371 |
分子量 | 488.67 |
分子式 | C29H40N6O |
CAS No. | 1429882-07-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 26.25 mg/mL (53.72 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.0464 mL | 10.2319 mL | 20.4637 mL | 51.1593 mL |
5 mM | 0.4093 mL | 2.0464 mL | 4.0927 mL | 10.2319 mL | |
10 mM | 0.2046 mL | 1.0232 mL | 2.0464 mL | 5.1159 mL | |
20 mM | 0.1023 mL | 0.5116 mL | 1.0232 mL | 2.558 mL | |
50 mM | 0.0409 mL | 0.2046 mL | 0.4093 mL | 1.0232 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
MRX-2843 1429882-07-4 Angiogenesis Others Tyrosine Kinase/Adaptors FLT UNC-2371 FLT3 MRX2843 Fms like tyrosine kinase 3 CD135 MRX 2843 inhibit Cluster of differentiation antigen 135 Inhibitor UNC2371 UNC 2371 inhibitor